Physician profile
Robin L Matson
NPI 1154378644
$5,624.17
in general payments reported to CMS, 2019-2025
47 companies · $934 in 2025
The $934 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $710 · 2021: $1,145 · 2022: $1,026 · 2023: $715 · 2024: $697 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.51 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $530.58 | 2021-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $310.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $306.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $287.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $268.29 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $232.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.63 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $155.06 | 2019-2020 | |
| Lilly USA, LLC | $151.89 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.53 | 2019-2024 | Relistor |
| Axsome Therapeutics, INC. | $139.71 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $136.00 | 2020-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $127.59 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.25 | 2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Matson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.